Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss, Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 11/30/-0001 |
| Start Date: | February 2009 |
The purpose of this study is to find out if spironolactone, a drug that blocks the action of
aldosterone, can make the blood vessels work better in people with obesity. The
investigators also want to find out whether spironolactone causes changes in levels of
insulin and markers of inflammation.
Inclusion Criteria:
1. Age 18-70 years
2. Good health as evidenced by history and physical exam
3. BMI: >30 kg/m2 and <45 kg/m2
Exclusion criteria:
1. Medical illnesses other than treated hypothyroidism
2. BP >135/85 or systolic BP <90 mm Hg
3. Hepatic disease (transaminase > 3 times normal)
4. Renal impairment (Creatinine clearance <60 ml/min)
5. Baseline serum K >5.0 mmol/L
6. History of drug or alcohol abuse
7. Allergies to spironolactone
8. Participation in any other concurrent clinical trial
9. Women using oral contraceptives within the last 3 months
We found this trial at
1
site
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
